Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on ProQR (PRQR – Research Report), Immunic (IMUX – Research Report) and Harmony Biosciences Holdings (HRMY – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ProQR (PRQR)
In a report released yesterday, Steven Seedhouse from Cantor Fitzgerald maintained a Buy rating on ProQR, with a price target of $8.00. The company’s shares closed last Tuesday at $1.46, close to its 52-week low of $1.40.
According to TipRanks.com, Seedhouse is a 4-star analyst with an average return of
ProQR has an analyst consensus of Strong Buy, with a price target consensus of $8.33.
See today’s best-performing stocks on TipRanks >>
Immunic (IMUX)
In a report released yesterday, Myles Minter from William Blair maintained a Buy rating on Immunic. The company’s shares closed last Tuesday at $0.84.
According to TipRanks.com, Minter is a 5-star analyst with an average return of
Immunic has an analyst consensus of Strong Buy, with a price target consensus of $5.50, implying a 547.1% upside from current levels. In a report issued on February 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.00 price target.
Harmony Biosciences Holdings (HRMY)
Truist Financial analyst Danielle Brill downgraded Harmony Biosciences Holdings to Hold yesterday. The company’s shares closed last Tuesday at $27.34.
According to TipRanks.com, Brill is a 4-star analyst with an average return of
Harmony Biosciences Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $45.60, a 64.9% upside from current levels. In a report issued on February 12, UBS also downgraded the stock to Hold with a $46.00 price target.
